Highest-materiality recent filing
Bankruptcy Court confirmed prepackaged Chapter 11 plan on July 21, 2026; company converted to New GoHealth, LLC.
GoHealth receives Nasdaq delisting notice after Chapter 11 filing; trading suspended June 16
Nasdaq delisting based on Chapter 11 filing, public interest concerns, and residual equity holder issues.
GoHealth files for Chapter 11 bankruptcy with prepackaged plan supported by 100% of lenders
GoHealth filed Chapter 11 on June 7, 2026; 100% of lenders, >60% of Class A common holders, and >99% of GoHealth Holdings unitholders support the prepackaged plan.
GoHealth receives Nasdaq delisting notice for failure to meet $35M market value requirement
Notice dated March 18, 2026 for non-compliance with MVLS Requirement (min $35M market value of listed securities).
Secured $115M superpriority term loan facility with $80M in new-money term loans and $35M in roll-up loans.
Extends revolving credit maturity from June 30 to September 30, 2025, and waives financial covenant testing for Q2 and Q3 2025.
GoHealth Q1 net revenue $221M (+19% YoY); Adjusted EBITDA $42.1M (+56%)
Net revenue $221.0M, up 19.1% YoY from $185.6M; net loss narrowed to $9.8M from $21.3M.
GoHealth extends CEO Kotte's contract to 2028; $1M salary, $5M equity, $3M cash retention
CEO term extended to April 1, 2028; base salary raised to $1M per year.
GoHealth Q4 net revenue up 41% to $389M; net income $58M vs prior year loss
Q4 net revenues $389.1M (+41% YoY); full-year net revenues $798.9M (+9% YoY).
GoHealth Q3 net income $15.4M vs loss $56.2M; acquires e-TeleQuote at bargain gain $77.4M
Q3 net revenues $118.3M, down $13.7M from $132.0M a year ago.
GoHealth closes acquisition of e-TeleQuote; gains ~$100M in contract assets and $18M cash
Acquisition closed on Sept 30, 2024; GoHealth invested $5M for newly issued shares and became sole owner after previous owner relinquished 81.1% stake.
GoHealth to acquire e-TeleQuote Insurance, gaining full ownership by Sept 30, 2024
GoHealth subsidiary will acquire newly issued shares representing ~18.9% of e-TeleQuote, then current parent surrenders all rights, making ETQ wholly-owned.
GoHealth Q2 2024 net revenues $105.9M, down 26% YoY; net loss improves to $59.3M
Net revenues of $105.9M, a decrease of $36.9M from $142.8M in Q2 2023.
GoHealth CFO Jason Schulz resigns; CAO Katherine O'Halloran named interim CFO
Jason Schulz resigned as CFO effective June 4, 2024, for personal reasons; no disagreement with company.
GoHealth Q1 net revenues $185.6M, up slightly; net loss narrows to $21.3M
Net revenues of $185.6M vs $183.2M in Q1 2023, a slight increase.
GoHealth reports Q4 net loss down 98.5% to $2.3M; FY 2023 Adj. EBITDA $75.1M
Q4 net revenues $276.7M vs $69.4M YoY; FY net rev $734.7M vs $631.7M.
GoHealth reports FY2023 cash from ops up 79% to $109.1M; Q4 rev $276.7M
Q4 2023 net revenue $276.7M vs $69.4M YoY; full-year $734.7M vs $631.7M.
GoHealth Q3 net loss narrows to $56.2M; submissions jump 31% YoY
Q3 2023 net revenues $132.0M vs $133.1M YoY; net loss improved to $56.2M from $74.7M.
GoHealth Q2 revenue falls 10% to $142.8M, but Adj EBITDA positive; rejects $20/share bid
Q2 net revenue $142.8M, down 10% YoY from $158.7M; net loss improved to $70.2M from $113.8M.
GoHealth Q1 net loss narrows to $22.5M; Adj EBITDA $28.8M, guides FY23 $750-850M revenue
Net loss of $22.5M (vs. -$37.2M YoY); net revenue $183.2M (down from $270.6M).
GoHealth Q4 net loss $150.7M, FY net loss $376.4M; guides 2023 rev $750-850M
Q4 net revenue $69.4M, net loss $150.7M, Adj EBITDA -$94.8M; FY net revenue $631.7M, net loss $376.4M, Adj EBITDA -$129.8M.
GoHealth reports positive FY2022 cash flow from operations, ahead of target
Positive cash flow from operations in FY2022, >$300M improvement vs FY2021, ahead of H1 2023 target.
Nasdaq granted additional 180 days until May 22, 2023 to meet minimum bid price of $1.00.
GoHealth announces 1-for-15 reverse stock split effective November 17, 2022
Stockholders approved reverse split ratio range of 1:5 to 1:15 at October 24 special meeting.
GoHealth Q3 net revenue down 37% to $133.1M; net loss widens to $74.7M
Medicare Submitted Policies Q3: 132,831, down 34% YoY; YTD up 11% to 611,385.
GoHealth shareholders approve reverse stock split at ratio between 1-for-5 and 1-for-15
Approximately 91% of outstanding shares voted; 288,575,991 for, 5,864,651 against, 192,740 abstain.
GoHealth receives $50M strategic investment from Anthem, issues 7% convertible preferred
Issued 50,000 shares of Series A Convertible Perpetual Preferred at $1,000/share for $50M total.
GoHealth amends credit agreement, raises interest rates on term loans to LIBOR+7.50%
Interest on 2021 Incremental Term Loans set to ABR+6.50% or LIBOR+7.50%.
GoHealth Q2 net revenue $158.7M (-19% YoY), net loss $113.8M; cuts 23.7% of workforce
Medicare Submitted Policies of 177,911 up 9% YoY; YTD up 38%.
GoHealth appoints new CEO and CFO; co-founders Jones and Cruz transition roles
Vijay Kotte appointed CEO effective June 6, 2022, succeeding Clinton P. Jones who becomes Executive Chair through Dec 31, 2022.
GoHealth receives Nasdaq minimum bid price deficiency notice; appoints David Fisher to board
Received Nasdaq notice for bid price below $1.00 for 30 consecutive days; compliance period through Nov 21, 2022.
GoHealth Q1 net revenue up 33% to $270.6M, but net loss widens to $37.2M; reaffirms FY guidance
Revenue $270.6M (+33% YoY); net loss $37.2M vs $7.3M loss in prior year.
GoHealth receives NASDAQ notice for audit committee noncompliance after director resignation
NASDAQ notified GoHealth on April 29, 2022 of noncompliance with Rule 5605(c)(2) requiring at least three independent audit committee members.
Immediately following such dissolution, the following individuals were appointed directors of Reorganized GoHealth: Vijay Kotte, Scott Avila, Neal Goldman and Conor Colpoys .
Immediately following such dissolution, the following individuals were appointed directors of Reorganized GoHealth: Vijay Kotte, Scott Avila, Neal Goldman and Conor Colpoys .
Immediately following such dissolution, the following individuals were appointed directors of Reorganized GoHealth: Vijay Kotte, Scott Avila, Neal Goldman and Conor Colpoys .
Immediately following such dissolution, the following individuals were appointed directors of Reorganized GoHealth: Vijay Kotte, Scott Avila, Neal Goldman and Conor Colpoys .
The Company and Michael Hargis, its Chief Operating Officer, agreed that Mr. Hargis will be leaving the Company to pursue other opportunities on June 5, 2026.
appointed Brendan Shanahan as the Company’s Chief Financial Officer, effective October 14, 2024
Ms. O’Halloran, the Company’s current Interim Chief Financial Officer, will continue her service to the Company as Chief Accounting Officer following Mr. Shanahan’s appointment as Chief Financial Officer.
On July 9, 2024, the Board of Directors (the “Board”) of GoHealth, Inc. (the “Company”) appointed Alan Wheatley as a Class II director of the Board, effective immediately.
On July 8, 2024, Christopher C. Litchford, a member of the Board, informed the Company of his intent to resign from the Board effective July 8, 2024.
On July 9, 2024, the Board appointed Abhiraj R. Modi as a Class II director of the Board.
Joseph G. Flanagan, a member of the Board of Directors (the “Board”) of GoHealth, Inc. (the “Company”), informed the Company of his intent to resign from the Board effective June 25, 2024.
Alexander Timm will replace Mr. Flanagan as lead independent director.
Max materiality 1.00 · Median 0.65 · Most common event earnings